NASDAQ: ESLAEstrella Immunopharma Inc Stock
$1.16+0.04 (+3.57%)
Updated May 8, 2025
ESLA Price
$1.16
Fair Value Price
$0.12
Market Cap
$41.95M
52 Week Low
$0.63
52 Week High
$3.23
P/E
-4.46x
P/B
291.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
20.85
Operating Cash Flow
-$8M
Beta
0.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ESLA Overview
TradeUP Acquisition Corporation is a 'blank check' company formed to effect mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar combinations with one or more businesses. It targets the tech sector. The company was incorporated in 2021 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ESLA's potential to beat the market
- ESLA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ESLA
RankedUnranked of 457
RankedUnranked of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important ESLA news, forecast changes, insider trades & much more!
ESLA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ESLA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESLA ($1.16) is overvalued by 880.29% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ESLA ($1.16) is not significantly undervalued (880.29%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ESLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ESLA due diligence checks available for Premium users.
Valuation
ESLA fair value
Fair Value of ESLA stock based on Discounted Cash Flow (DCF)
Price
$1.16
Fair Value
$0.12
Overvalued by
880.29%
ESLA ($1.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ESLA ($1.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ESLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ESLA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.46x
Industry
-168.76x
Market
24.22x
ESLA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
291.88x
Industry
4.15x
ESLA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ESLA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.1M
Profit Margin
0%
ESLA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.1M
Liabilities
$3.0M
Debt to equity
20.85
ESLA's short-term liabilities ($3.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESLA's short-term assets ($1.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESLA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$896.1k
Investing
$0.0
Financing
$15.5k
ESLA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESLA vs Biotech Stocks
Estrella Immunopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.